Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 229

Similar articles for PubMed (Select 16715866)

1.

[Use of rofecoxib in family practice in the north of Netherlands, 2000-2004: background and consequences].

van der Veen WJ, van der Werf GT.

Ned Tijdschr Geneeskd. 2006 May 6;150(18):1016-21. Dutch.

PMID:
16715866
2.

Factors associated with celecoxib and rofecoxib utilization.

Rawson NS, Nourjah P, Grosser SC, Graham DJ.

Ann Pharmacother. 2005 Apr;39(4):597-602. Epub 2005 Mar 8.

PMID:
15755796
3.

Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.

Moride Y, Ducruet T, Boivin JF, Moore N, Perreault S, Zhao S.

Arthritis Res Ther. 2005;7(2):R333-42. Epub 2005 Jan 17.

4.

Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.

Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J.

Pharmacoepidemiol Drug Saf. 2007 May;16(5):493-503.

PMID:
17086567
5.

The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.

Florentinus SR, Heerdink ER, de Boer A, van Dijk L, Leufkens HG.

Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):437-41. Erratum in: Pharmacoepidemiol Drug Saf. 2005 Sep;14(9):669.

PMID:
15937867
6.
7.

Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.

Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S.

Arthritis Rheum. 2006 May;54(5):1378-89.

8.

Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.

Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S.

Pharmacotherapy. 2009 Dec;29(12):1397-407. doi: 10.1592/phco.29.12.1397.

PMID:
19947799
9.

Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.

Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.

Circulation. 2006 Jun 27;113(25):2906-13. Epub 2006 Jun 19.

10.

Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.

Andersohn F, Schade R, Suissa S, Garbe E.

Stroke. 2006 Jul;37(7):1725-30. Epub 2006 May 25.

12.

Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile.

Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Verma A, Rothman KJ.

Pharmacoepidemiol Drug Saf. 2006 Dec;15(12):861-72.

PMID:
17086563
13.

[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].

Valat JP, Deray G, Héloire F.

Presse Med. 2006 Sep;35 Suppl 1:25-34. Review. French.

PMID:
17870550
14.

[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].

Valat JP, Deray G, Héloire F.

Presse Med. 2006 Sep;35(9 Spec No 1):1S25-34. Review. French.

PMID:
17078592
15.

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.

Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT.

Arch Intern Med. 2005 May 9;165(9):978-84.

PMID:
15883235
16.

Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib.

Setakis E, Leufkens HG, van Staa TP.

Arthritis Rheum. 2008 Aug 15;59(8):1105-11. doi: 10.1002/art.23925.

17.

Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors.

Lévesque LE, Brophy JM, Zhang B.

CMAJ. 2006 May 23;174(11):1563-9. Epub 2006 May 2.

18.

Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.

Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Stanley A, Stokes JC, Julier P, Iveson C, Duvvuri R, McConkey CC; VICTOR Trial Group.

N Engl J Med. 2007 Jul 26;357(4):360-9.

19.

Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study.

Depont F, Fourrier A, Merlière Y, Droz C, Amouretti M, Bégaud B, Bénichou J, Moride Y, Velo GP, Sturkenboom M, Blin P, Moore N; CADEUS Team.

Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):891-900.

PMID:
17351983
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk